MA45498A - Cellules treg génétiquement modifiées - Google Patents

Cellules treg génétiquement modifiées

Info

Publication number
MA45498A
MA45498A MA045498A MA45498A MA45498A MA 45498 A MA45498 A MA 45498A MA 045498 A MA045498 A MA 045498A MA 45498 A MA45498 A MA 45498A MA 45498 A MA45498 A MA 45498A
Authority
MA
Morocco
Prior art keywords
genetically modified
treg cells
modified treg
cells
genetically
Prior art date
Application number
MA045498A
Other languages
English (en)
Inventor
Takatoshi Chinen
Alexander Y Rudensky
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MA45498A publication Critical patent/MA45498A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
MA045498A 2016-06-16 2017-06-15 Cellules treg génétiquement modifiées MA45498A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662351104P 2016-06-16 2016-06-16

Publications (1)

Publication Number Publication Date
MA45498A true MA45498A (fr) 2019-04-24

Family

ID=60663377

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045498A MA45498A (fr) 2016-06-16 2017-06-15 Cellules treg génétiquement modifiées

Country Status (8)

Country Link
US (1) US20190322983A1 (fr)
EP (1) EP3472305A4 (fr)
JP (2) JP2019518460A (fr)
CN (1) CN109415698A (fr)
AU (1) AU2017285319A1 (fr)
CA (1) CA3027546A1 (fr)
MA (1) MA45498A (fr)
WO (1) WO2017218850A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7213799B2 (ja) * 2016-10-10 2023-01-27 ザ ナショナル インスティチュート フォー バイオテクノロジー イン ザ ネゲヴ，リミテッド 非細胞傷害性改変細胞およびその使用
GB201714718D0 (en) 2017-09-13 2017-10-25 Autolus Ltd Cell
WO2019178518A1 (fr) * 2018-03-16 2019-09-19 The Regents Of The University Of California Modification de domaine de signalisation cellulaire dans des lymphocytes t régulateurs modifiés par un récepteur antigénique chimérique
KR20210043574A (ko) 2018-07-09 2021-04-21 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 푸소좀 조성물 및 이의 용도
GB201814203D0 (en) * 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell
US20230043255A1 (en) 2018-11-14 2023-02-09 Flagship Pioneering Innovations V, Inc. Fusosome compositions for t cell delivery
KR20210125509A (ko) * 2019-02-01 2021-10-18 케이에스큐 세러퓨틱스 인코포레이티드 개선된 면역요법을 위한 유전자-조절 조성물 및 방법
US11160832B2 (en) 2019-07-09 2021-11-02 The Children's Mercy Hospital Engineered regulatory T cells
WO2021154882A1 (fr) * 2020-01-27 2021-08-05 H. Lee Moffitt Cancer Center And Research Institute Inc. Lymphocytes t régulateurs humains inhibés par hdac6
TW202146431A (zh) 2020-02-25 2021-12-16 英商圭爾醫療有限公司 用於經工程化細胞之嵌合受體
GB202102637D0 (en) 2021-02-24 2021-04-07 Quell Therapeutics Ltd Engineered regulatory t cell
IL322256A (en) 2023-01-23 2025-09-01 Medizinische Hochschule Hannover Anti-ENTPD3 chimeric antigen receptor
EP4403580A1 (fr) 2023-01-23 2024-07-24 Medizinische Hochschule Hannover Anti-entpd3 récepteur antigénique chimérique
IL322333A (en) 2023-02-07 2025-09-01 Quell Therapeutics Ltd Culture method for TREG cells
EP4420676A1 (fr) 2023-02-24 2024-08-28 Medizinische Hochschule Hannover Récepteur antigénique chimérique
WO2024175805A1 (fr) 2023-02-24 2024-08-29 Medizinische Hochschule Hannover Récepteur antigénique chimérique
WO2024194605A1 (fr) 2023-03-17 2024-09-26 Quell Therapeutics Limited Thérapie treg
EP4434539A1 (fr) 2023-03-20 2024-09-25 Medizinische Hochschule Hannover Récepteur antigénique chimérique
CN121586582A (zh) 2023-03-20 2026-02-27 汉诺威医学院 嵌合抗原受体
WO2026008994A1 (fr) 2024-07-04 2026-01-08 Quell Therapeutics Limited Construction d'expression
GB202411558D0 (en) 2024-08-06 2024-09-18 Quell Therapeutics Ltd Culture method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235873B1 (en) * 1999-07-31 2001-05-22 The Rockefeller University Constitutively active transcription factors and their uses for identifying modulators of activity including dysproliferative cellular changes
JP2010531138A (ja) * 2007-06-13 2010-09-24 ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー 制御性ｔ細胞ならびに同製造および使用方法
US8658159B2 (en) * 2008-06-30 2014-02-25 Versitech Limited Method to induce and expand therapeutic alloantigen-specific human regulatory T cells in large-scale
CN107106665A (zh) * 2014-06-06 2017-08-29 纪念斯隆-凯特琳癌症中心 靶向间皮素的嵌合抗原受体及其用途
US20180134795A1 (en) * 2014-06-17 2018-05-17 Cellectis Cd123 specific multi-chain chimeric antigen receptor
US11111505B2 (en) * 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof

Also Published As

Publication number Publication date
JP2022058995A (ja) 2022-04-12
CN109415698A (zh) 2019-03-01
EP3472305A1 (fr) 2019-04-24
CA3027546A1 (fr) 2017-12-21
EP3472305A4 (fr) 2020-01-15
WO2017218850A1 (fr) 2017-12-21
JP2019518460A (ja) 2019-07-04
US20190322983A1 (en) 2019-10-24
AU2017285319A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
MA45498A (fr) Cellules treg génétiquement modifiées
IL262772A (en) Genetically engineered cells and methods of making the same
NO2025012I1 (no) Autologous anti-CD19-transduced CD3+ cells (brexucabtagene autoleucel)
EP3562492A4 (fr) Cellules tueuses naturelles génétiquement modifiées
IL292828A (en) Central memory t cells for adoptive t cell therapy
MA46959A (fr) Cellules b modifiées et compositions et méthodes associées
IL259586B (en) Genetically modified stem cells and uses thereof
IL262359A (en) Ex vivo bite-activated t cells
EP3471772A4 (fr) Compositions et méthodes de déplétion de cellules
EP3858365C0 (fr) Lymphocytes t car optimisés avec de l'or
EP3411079A4 (fr) Cellules mammifères génétiquement modifiées pour thérapie anticancéreuse
EP3507831A4 (fr) Cellules de mémoire et matrices mémoire
IL254734B1 (en) Modified t cells and methods of making and using the same
EP3507832A4 (fr) Cellules de mémoire et matrices mémoire
EP3443506C0 (fr) Neurone artificiel
EP4212613C0 (fr) Matrice de croissance cellulaire
EP3426690A4 (fr) Cellules effectrices immunes éditées par le génome
HUE053101T2 (hu) Javított T-sejt-készítmények
IL249970B (en) Gamma delta t cells and uses thereof
EP3573464A4 (fr) Ingénierie de cellules b
EP3475413C0 (fr) Lymphocytes t génétiquement modifiés
IL261710A (en) Production of antigen-specific t-cells
HUE053760T2 (hu) SUV39h1-deficiens immunsejtek
EP3455344A4 (fr) Cellules souches/progénitrices hématopoïétiques
EP3475986A4 (fr) Interconnexion cellule-à-cellule